Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/25/2026

1. QCOM
2. MU
3. CBRS
4. HTZ
5. FDX
6. USO
7. SPY
8. KBH
9. LAES
10. HON

Go back to Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
TRANS-LUX CORPORATION (NASDAQ: TLX) Delayed: 10.90 +0.69 (6.76%)
Previous Close $10.21    52 Week High $2.18 
Open $10.81    52 Week Low $0.30 
Day High $11.07    P/E N/A 
Day Low $10.74    EPS $-3.32 
Volume 202,556       

TRANS-LUX CORPORATION (NASDAQ: TLX) Delayed: 10.90 +0.69 (6.76%)
Previous Close $10.21    52 Week High $2.18 
Open $10.81    52 Week Low $0.30 
Day High $11.07    P/E N/A 
Day Low $10.74    EPS $-3.32 
Volume 202,556